References
1. Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S,
Middeldorp S, et al. ESHRE guideline: recurrent pregnancy loss. Human
reproduction open. 2018;2018(2):hoy004.
2. Li J, Gu Y, Zhang S, Ju B, Wang J. Effect of Prepregnancy Lymphocyte
Active Immunotherapy on Unexplained Recurrent Miscarriage, Pregnancy
Success Rate, and Maternal-Infant Outcome. BioMed research
international. 2021;2021:7878752.
3. La X, Wang W, Zhang M, Liang L. Definition and Multiple Factors of
Recurrent Spontaneous Abortion. Advances in experimental medicine and
biology. 2021;1300:231-57.
4. Dimitriadis E, Menkhorst E, Saito S, Kutteh WH, Brosens JJ. Recurrent
pregnancy loss. Nature reviews Disease primers. 2020;6(1):98.
5. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor
(TAFI, plasma procarboxypeptidase B, procarboxypeptidase R,
procarboxypeptidase U). Journal of thrombosis and haemostasis : JTH.
2003;1(7):1566-74.
6. Sillen M, Declerck PJ. Thrombin Activatable Fibrinolysis Inhibitor
(TAFI): An Updated Narrative Review. International journal of molecular
sciences. 2021;22(7).
7. Schneider M, Nesheim M. A study of the protection of plasmin from
antiplasmin inhibition within an intact fibrin clot during the course of
clot lysis. The Journal of biological chemistry. 2004;279(14):13333-9.
8. Silva MM, Thelwell C, Williams SC, Longstaff C. Regulation of
fibrinolysis by C-terminal lysines operates through plasminogen and
plasmin but not tissue-type plasminogen activator. Journal of thrombosis
and haemostasis : JTH. 2012;10(11):2354-60.
9. Plug T, Meijers JC. Structure-function relationships in
thrombin-activatable fibrinolysis inhibitor. Journal of thrombosis and
haemostasis : JTH. 2016;14(4):633-44.
10. Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL, et
al. The thrombomodulin-protein C system is essential for the maintenance
of pregnancy. Nature medicine. 2003;9(3):331-7.
11. Legnani C, Bovara M, Valdrè L, Cosmi B, Caniato A, Palareti G. Risk
of early recurrent fetal loss and levels of thrombin-activatable
fibrinolysis inhibitor. Thrombosis research. 2012;130(2):237-41.
12. Folkeringa N, Korteweg FJ, Veeger NJ, Middeldorp S, Hamulyak K,
Prins MH, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) is
not associated with fetal loss, a retrospective study. Thrombosis
research. 2009;123(3):511-4.
13. Yildirim MN, Selcoki Y, Uysal S, Nacar AB, Demircelik B, Aydin HI,
et al. Thrombin activatable fibrinolysis inhibitor : its role in slow
coronary flow. Herz. 2014;39(8):993-1000.
14. He H, Jing S, Gong F, Tan YQ, Lu GX, Lin G. Effect of thyroid
autoimmunity per se on assisted reproduction treatment outcomes: A
meta-analysis. Taiwanese journal of obstetrics & gynecology.
2016;55(2):159-65.
15. Dhillon-Smith RK, Coomarasamy A. TPO antibody positivity and adverse
pregnancy outcomes. Best practice & research Clinical endocrinology &
metabolism. 2020;34(4):101433.
16. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et
al. 2017 Guidelines of the American Thyroid Association for the
Diagnosis and Management of Thyroid Disease During Pregnancy and the
Postpartum. Thyroid : official journal of the American Thyroid
Association. 2017;27(3):315-89.
17. Iravani AT, Saeedi MM, Pakravesh J, Hamidi S, Abbasi M. Thyroid
autoimmunity and recurrent spontaneous abortion in Iran: a case-control
study. Endocrine practice : official journal of the American College of
Endocrinology and the American Association of Clinical Endocrinologists.
2008;14(4):458-64.
18. Hooper JM, Stuijver DJ, Orme SM, van Zaane B, Hess K, Gerdes VE, et
al. Thyroid dysfunction and fibrin network structure: a mechanism for
increased thrombotic risk in hyperthyroid individuals. The Journal of
clinical endocrinology and metabolism. 2012;97(5):1463-73.
19. Morser J, Gabazza EC, Myles T, Leung LL. What has been learnt from
the thrombin-activatable fibrinolysis inhibitor-deficient mouse? Journal
of thrombosis and haemostasis : JTH. 2010;8(5):868-76.
20. Naito M, Taguchi O, Kobayashi T, Takagi T, D’Alessandro-Gabazza CN,
Matsushima Y, et al. Thrombin-activatable fibrinolysis inhibitor
protects against acute lung injury by inhibiting the complement system.
American journal of respiratory cell and molecular biology.
2013;49(4):646-53.
21. Yoshida K, Takabayashi T, Imoto Y, Sakashita M, Kato Y, Narita N, et
al. Increased Thrombin-Activatable Fibrinolysis Inhibitor in Response to
Sublingual Immunotherapy for Allergic Rhinitis. The Laryngoscope.
2021;131(11):2413-20.
22. Mook-Kanamori BB, Valls Serón M, Geldhoff M, Havik SR, van der Ende
A, Baas F, et al. Thrombin-activatable fibrinolysis inhibitor influences
disease severity in humans and mice with pneumococcal meningitis.
Journal of thrombosis and haemostasis : JTH. 2015;13(11):2076-86.
23. Chen L, Hu R. Thyroid autoimmunity and miscarriage: a meta-analysis.
Clinical endocrinology. 2011;74(4):513-9.
24. Chardès T, Chapal N, Bresson D, Bès C, Giudicelli V, Lefranc MP, et
al. The human anti-thyroid peroxidase autoantibody repertoire in Graves’
and Hashimoto’s autoimmune thyroid diseases. Immunogenetics.
2002;54(3):141-57.
25. Warren BB, Moyer GC, Manco-Johnson MJ. Hemostasis in the Pregnant
Woman, the Placenta, the Fetus, and the Newborn Infant. Seminars in
thrombosis and hemostasis. 2023;49(4):319-29.
26. Knol HM, Veeger NJ, Middeldorp S, Hamulyák K, Van Der Meer J. High
thrombin-activatable fibrinolysis inhibitor levels may protect against
recurrent fetal loss. Journal of thrombosis and haemostasis : JTH.
2009;7(5):903-6.
27. Masini S, Ticconi C, Gravina P, Tomassini M, Pietropolli A, Forte V,
et al. Thrombin-activatable fibrinolysis inhibitor polymorphisms and
recurrent pregnancy loss. Fertil Steril. 2009;92(2):694-702.
28. Eser A, Inegol Gumus I, Erdamar H, Kaygusuz I, Yildirim M,
Usluogullari B, et al. Levels of thrombin-activatable fibrinolysis
inhibitor and platelet-activating factor in recurrent pregnancy loss
patients. Taiwanese journal of obstetrics & gynecology.
2016;55(1):60-3.
29. Martínez-Zamora MA, Creus M, Tassies D, Bové A, Reverter JC, Carmona
F, et al. Thrombin activatable fibrinolysis inhibitor and clot lysis
time in women with recurrent miscarriage associated with the
antiphospholipid syndrome. Fertil Steril. 2010;94(6):2437-40.
30. Schroeder V, Wilmer M, Buehler B, Kohler HP. TAFI activity in
coronary artery disease: a contribution to the current discussion on
TAFI assays. Thrombosis and haemostasis. 2006;96(2):236-7.
31. Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in
measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in
understanding its molecular genetics, gene regulation, and biological
roles. Clinical biochemistry. 2007;40(7):431-42.
32. Grosso G, Vikerfors A, Woodhams B, Adam M, Bremme K, Holmström M, et
al. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link
between coagulation and complement activation in the antiphospholipid
syndrome (APS). Thrombosis research. 2017;158:168-73.
33. Ermantas N, Guldiken S, Demir M, Tugrul A. Thrombin-activatable
fibrinolysis inhibitor (TAFI) antigen and activity assay in patients
with primary hypothyroidism. Clinical and applied thrombosis/hemostasis
: official journal of the International Academy of Clinical and Applied
Thrombosis/Hemostasis. 2010;16(5):568-73.
34. Ellervik C, Mora S, Kuś A, Åsvold B, Marouli E, Deloukas P, et al.
Effects of Thyroid Function on Hemostasis, Coagulation, and
Fibrinolysis: A Mendelian Randomization Study. Thyroid : official
journal of the American Thyroid Association. 2021;31(9):1305-15.